MX2021007258A - Composiciones de esparsentan amorfas. - Google Patents
Composiciones de esparsentan amorfas.Info
- Publication number
- MX2021007258A MX2021007258A MX2021007258A MX2021007258A MX2021007258A MX 2021007258 A MX2021007258 A MX 2021007258A MX 2021007258 A MX2021007258 A MX 2021007258A MX 2021007258 A MX2021007258 A MX 2021007258A MX 2021007258 A MX2021007258 A MX 2021007258A
- Authority
- MX
- Mexico
- Prior art keywords
- amorphous
- sparsentan
- compositions
- disorders
- compounds
- Prior art date
Links
- WRFHGDPIDHPWIQ-UHFFFAOYSA-N 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-n-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O=C1N(CC=2C=C(COCC)C(=CC=2)C=2C(=CC=CC=2)S(=O)(=O)NC=2C(=C(C)ON=2)C)C(CCCC)=NC21CCCC2 WRFHGDPIDHPWIQ-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229950002009 sparsentan Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000017169 kidney disease Diseases 0.000 abstract 2
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783947P | 2018-12-21 | 2018-12-21 | |
| PCT/US2019/068094 WO2020132594A1 (en) | 2018-12-21 | 2019-12-20 | Amorphous sparsentan compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021007258A true MX2021007258A (es) | 2021-08-16 |
Family
ID=69187971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007258A MX2021007258A (es) | 2018-12-21 | 2019-12-20 | Composiciones de esparsentan amorfas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220048900A1 (https=) |
| EP (1) | EP3897834A1 (https=) |
| JP (1) | JP2022514569A (https=) |
| KR (1) | KR20210125994A (https=) |
| CN (1) | CN114126712A (https=) |
| AU (1) | AU2019404552A1 (https=) |
| BR (1) | BR112021012226A2 (https=) |
| CA (1) | CA3124127A1 (https=) |
| IL (1) | IL284186A (https=) |
| MA (1) | MA54542A (https=) |
| MX (1) | MX2021007258A (https=) |
| WO (1) | WO2020132594A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53817A (fr) | 2018-10-04 | 2021-08-11 | Travere Therapeutics Inc | Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv |
| WO2022266370A1 (en) | 2021-06-17 | 2022-12-22 | Aria Pharmaceuticals, Inc. | Sparsentan for treating idiopathic pulmonary fibrosis |
| EP4458826A4 (en) * | 2021-12-28 | 2025-12-24 | Alchemedicine Inc | COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION |
| JP2025183466A (ja) * | 2022-11-11 | 2025-12-17 | 株式会社アークメディスン | 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物 |
| KR20250151548A (ko) * | 2023-02-24 | 2025-10-21 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 방향족 고리계 함유 유도체 길항제의 염, 이의 제조 방법과 응용 |
| CN118666826A (zh) * | 2024-08-23 | 2024-09-20 | 成都臻拓医药科技有限公司 | 一种司帕生坦原料药的重结晶纯化方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6638937B2 (en) | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| ATE339417T1 (de) * | 1999-12-15 | 2006-10-15 | Bristol Myers Squibb Co | Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten |
| WO2010114801A1 (en) * | 2009-03-31 | 2010-10-07 | Ligand Pharmaceuticals Inc. | Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy |
| WO2010135350A2 (en) * | 2009-05-20 | 2010-11-25 | Pharmacopeia, Llc | Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist |
| CN117017985A (zh) * | 2016-10-13 | 2023-11-10 | 特拉维尔治疗公司 | 用于治疗肾脏疾病或病症的联苯磺酰胺化合物 |
-
2019
- 2019-12-20 US US17/415,518 patent/US20220048900A1/en not_active Abandoned
- 2019-12-20 AU AU2019404552A patent/AU2019404552A1/en not_active Abandoned
- 2019-12-20 MX MX2021007258A patent/MX2021007258A/es unknown
- 2019-12-20 MA MA054542A patent/MA54542A/fr unknown
- 2019-12-20 WO PCT/US2019/068094 patent/WO2020132594A1/en not_active Ceased
- 2019-12-20 CA CA3124127A patent/CA3124127A1/en active Pending
- 2019-12-20 JP JP2021535041A patent/JP2022514569A/ja active Pending
- 2019-12-20 CN CN201980092448.1A patent/CN114126712A/zh active Pending
- 2019-12-20 BR BR112021012226-5A patent/BR112021012226A2/pt not_active IP Right Cessation
- 2019-12-20 EP EP19842514.2A patent/EP3897834A1/en not_active Withdrawn
- 2019-12-20 KR KR1020217021973A patent/KR20210125994A/ko not_active Ceased
-
2021
- 2021-06-20 IL IL284186A patent/IL284186A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3124127A1 (en) | 2020-06-25 |
| US20220048900A1 (en) | 2022-02-17 |
| EP3897834A1 (en) | 2021-10-27 |
| BR112021012226A2 (pt) | 2021-09-08 |
| KR20210125994A (ko) | 2021-10-19 |
| AU2019404552A1 (en) | 2021-07-15 |
| IL284186A (en) | 2021-08-31 |
| WO2020132594A1 (en) | 2020-06-25 |
| JP2022514569A (ja) | 2022-02-14 |
| CN114126712A (zh) | 2022-03-01 |
| MA54542A (fr) | 2021-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021007258A (es) | Composiciones de esparsentan amorfas. | |
| ZA202206923B (en) | New methylquinazolinone derivatives | |
| EP4252848A3 (en) | Oxysterols and methods of use thereof | |
| MX2020001776A (es) | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. | |
| MX2023002004A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| EP4442695A3 (en) | 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders | |
| EA202092253A1 (ru) | Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5 | |
| EP4609866A3 (en) | Oxysterols and methods of use thereof | |
| EP4321513A3 (en) | Pyrrolotriazine compounds as tam inhibitors | |
| EP4360707A3 (en) | Compositions for treating spinal muscular atrophy | |
| EP4365179A3 (en) | Novel rapamycin derivatives | |
| EP4316591A3 (en) | Oxysterols and methods of use thereof | |
| MX2016017147A (es) | Compuestos de indazole substituidos como inhibidores de irak4. | |
| EP4599887A8 (en) | Oxysterols and methods of use thereof | |
| MX2017007607A (es) | Inhibidores de necrosis celular y metodos relacionados. | |
| MX2024009925A (es) | Composiciones y metodos para tratar trastornos del snc. | |
| EA202191519A1 (ru) | Модуляторы trex1 | |
| EA201791802A1 (ru) | СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| ZA202305624B (en) | Amorphous form of a complement component c5a receptor | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| PH12017501652B1 (en) | Kv1.3 inhibitors and their medical application | |
| NZ758449A (en) | Heteroaromatic compounds useful in therapy |